Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

NCT03380390 PHASE4 COMPLETED Results posted

This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.

Details

Lead sponsor	Aclaris Therapeutics, Inc.
Phase	PHASE4
Status	COMPLETED
Enrolment	46
Start date	Mon Dec 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Rosacea

Interventions

• Oxymetazoline HCL 1.0% Cream
• Energy-Based Therapy

Countries

United States